Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids
Articles > Article · 2021
Authors: Ezgi Oner, Mustafa KOTMAKÇI, Anne-Marie Baird, Steven G. Gray, Bilge DEBELEÇ BÜTÜNER, Emir Bozkurt, Ayşe Gülten KANTARCI, Stephen P. Finn
JOURNAL OF NANOBIOTECHNOLOGY, Journal Indexed in SCI Expanded, International, Scopus, 2021, vol 19, pp 71-71
DOI: 10.1186/s12951-021-00781-z
Summary
Background: siRNAs hold a great potential for cancer therapy, however, poor stability in body fluids and low cellular uptake limit their use in the clinic. To enhance the bioavailability of siRNAs in tumors, novel, safe, and effective carriers are needed.